Eli Lilly (LLY) on Solana

The FDA has approved an expanded label for Eli Lilly's Mounjaro (tirzepatide) to include reduction of cardiovascular events in adults with type 2 diabetes, moving the drug beyond its original blood sugar control indication. Mounjaro is now the first dual GIP and GLP-1 receptor agonist to carry a cardiovascular risk reduction claim, a milestone that meaningfully widens the eligible patient population and opens Lilly to new prescribing and payer conversations in cardiology alongside endocrinology.

For Eli Lilly's pipeline and commercial strategy, the label addition deepens Mounjaro's role within the company's dominant incretin franchise while sharpening its differentiation against GLP-1 rivals that lack the dual-agonist mechanism. Analysts are watching whether quarterly filings begin reflecting Mounjaro share gains in the cardiometabolic segment as prescribers respond to the broader indication — a critical variable for assessing how much of Lilly's increasingly concentrated GLP-1 revenue base can sustain long-term growth.

Eli Lilly's GLP-1 franchise now drives roughly two-thirds of total revenue, with Mounjaro and Zepbound together generating nearly $15 billion of the company's approximately $23 billion in Q2 2026 quarterly sales. That concentration is a double-edged dynamic: it has powered outsized growth, but it also means any stumble in the weight-loss drug market — from pricing pressure, coverage pullbacks, or a better competitor — hits the whole business hard. The recent launch of Foundayo, an oral GLP-1 pill, extends Lilly's product range but does not reduce the category dependence.

Growth rates are already moderating: Zepbound's year-over-year gain slowed from 172% in Q2 2025 to 46% in Q2 2026, a deceleration that reflects the natural math of a large installed base even as the drug remains a commercial success. To get ahead of this inevitable plateau, Lilly has been aggressively directing GLP-1 profits toward acquisitions into new therapeutic areas — a sensible diversification play, though drug development pipelines carry their own execution risk and most candidates fail before reaching market.

Employer coverage of GLP-1 weight-loss medications dropped from 72% in 2025 to 60% in 2026, with roughly 14% of surveyed employers either already dropping coverage or planning to do so by 2027. The pullback stems from employers weighing high upfront drug costs against uncertain long-term savings on diabetes, sleep apnea, and obesity-related complications — a calculus that continues to favor cost-cutting despite broad acknowledgment of the drugs' efficacy.

Eli Lilly has largely insulated itself from the coverage contraction through a volume-driven shift toward cash-pay channels. In Q2, Zepbound generated $4.93 billion in obesity revenue and Mounjaro $9.94 billion in type 2 diabetes revenue, lifting total company revenue to $22.97 billion — up 47.67% year over year. Approximately 45% of all Zepbound prescriptions and 55% of new ones were self-pay during the quarter, with a 60% increase in volume more than offsetting a 13% decline in realized prices. Lilly has also expanded access programs to support this shift, including Employer Connect at $449 per month, a Medicare GLP-1 Bridge program at $50 per month, and broadening state Medicaid pathways.

Eli Lilly lifted its full-year 2026 revenue guidance by roughly 3% and raised its performance margin target by 2 percentage points following a Q2 report in which revenue grew 48% year-over-year, driven by incretin drugs Mounjaro and Zepbound. Despite the upward revision, earnings per share guidance was modestly trimmed, and the stock's muted post-earnings drift — gains of 4.9% on results day and a further 7.5% afterward — fell short of the enthusiasm some investors anticipated after the stock had already climbed 79% over the prior year.

Analysts pointed to two headwinds tempering the enthusiasm: the oral weight-loss pill Foundayo is launching more slowly than expected, and management's own implied guidance suggests growth could decelerate in the second half of 2026. Options markets priced implied volatility at a relatively subdued 32nd percentile, signaling traders expect relative calm rather than a breakout move. The broad takeaway from market observers is that Lilly's execution remains strong, but after a near-doubling in share price, much of the good news was already reflected in the valuation before the report landed.

Eli Lilly's oral GLP-1 weight-loss pill Foundayo (orforglipron) became available in UK pharmacies on August 24, 2026, marking the drug's commercial debut following its MHRA approval earlier this month. The once-daily tablet, which mimics the GLP-1 hormone to reduce hunger and promote satiety, is available via private prescription only and is not yet covered by the NHS. It is indicated for adults with a BMI of at least 30, or 27–30 with weight-related conditions, alongside diet and exercise; it also carries authorization to improve blood sugar control in adults with inadequately controlled type 2 diabetes. Patients begin on a 0.8 mg starting dose that is gradually titrated upward, and unlike injectable GLP-1 therapies, the pill can be taken at any time of day without food or water restrictions.

The UK launch makes Eli Lilly the first company to bring an oral small-molecule GLP-1 receptor agonist to a European market, intensifying competition with Novo Nordisk in the rapidly expanding weight management category. Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain — a tolerability profile consistent with other drugs in the class.

Citadel Advisors, Ken Griffin's hedge fund, added approximately 704,000 shares of Eli Lilly (LLY) in Q2 2026, nearly quadrupling its existing position and making LLY Citadel's sixth-largest holding. The purchases appear to have been made in late April, when LLY was trading down roughly 21% year-to-date, suggesting an opportunistic entry during a period of weakness.

The bull case centers on Lilly's tirzepatide franchise: Mounjaro and Zepbound are tracking toward combined sales of over $55 billion for the full year. The recently approved oral GLP-1 pill Foundayo adds another growth layer, with analysts projecting $1.5 billion in 2026 revenue and peak annual sales potential of $26 billion. A retatrutide approval filing is expected in Q1 2027, further underpinning the pipeline. Despite these growth drivers, LLY shares trade at approximately 35x forward earnings — a premium that reflects both current momentum and the scale of the obesity drug opportunity still ahead.

Eli Lilly has entered a global collaboration and license agreement with OmniAb to support a new ion channel drug discovery program, broadening Lilly's early-stage pipeline beyond its GLP-1 franchise. Under the deal, OmniAb will contribute its antibody discovery platform and ion channel expertise to drive the research program; the specific therapeutic target has not been disclosed.

Financial terms include an undisclosed upfront payment to OmniAb along with potential milestone payments of up to $370 million across research, development, and commercial stages, plus tiered royalties on global net sales. The partnership extends Lilly's strategy of sourcing early discovery capabilities externally while retaining global commercialization rights, and positions the company in the ion channel space where significant unmet medical needs remain.